Nuformix plc (LON:NFX – Get Free Report)’s share price traded up 18.6% during trading on Monday . The company traded as high as GBX 0.07 ($0.00) and last traded at GBX 0.07 ($0.00). 65,650 shares traded hands during trading, a decline of 99% from the average session volume of 5,787,441 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Performance
The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The firm has a 50-day moving average price of GBX 0.12 and a two-hundred day moving average price of GBX 0.17. The firm has a market cap of £491,586.00, a PE ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- 3 Warren Buffett Stocks to Buy Now
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- High Dividend REITs: Are They an Ideal Way to Diversify?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Retail Stocks Investing, Explained
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
